{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:39:47Z","timestamp":1766407187695,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003053","name":"Alberta Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jval.2020.10.004","type":"journal-article","created":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T08:17:16Z","timestamp":1605341836000},"page":"50-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model"],"prefix":"10.1016","volume":"24","author":[{"given":"Ellen R.S.","family":"Rafferty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wade","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel D.","family":"Osgood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Doroshenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa","family":"Farag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2020.10.004_bib1","first-page":"241","article-title":"The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013","volume":"73","author":"Hobbelen","year":"2016","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.jval.2020.10.004_bib2","series-title":"Vaccines","first-page":"837","article-title":"Varicella vaccine","author":"Gershon","year":"2012"},{"key":"10.1016\/j.jval.2020.10.004_bib3","first-page":"1","article-title":"An Advisory Committee Statement (ACS): statement on the recommended use of varicella virus vaccine","volume":"25","year":"1999","journal-title":"Canada Commun Dis Rep"},{"issue":"RR11","key":"10.1016\/j.jval.2020.10.004_bib4","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"45","year":"1996","journal-title":"MMWR"},{"issue":"2","key":"10.1016\/j.jval.2020.10.004_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/INF.0000000000002233","article-title":"Implementing universal varicella vaccination in Europe: the path forward","volume":"38","author":"Spoulou","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jval.2020.10.004_bib6","first-page":"1","article-title":"An advisory committee statement: update on varicella","volume":"30","year":"2004","journal-title":"Canada Commun Dis Rep"},{"author":"Lieu","key":"10.1016\/j.jval.2020.10.004_bib7"},{"issue":"9","key":"10.1016\/j.jval.2020.10.004_bib8","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.4161\/hv.25228","article-title":"Economic evaluation of varicella vaccination: results of a systematic review","volume":"9","author":"Unim","year":"2013","journal-title":"Hum Vaccines Immunother"},{"issue":"6","key":"10.1016\/j.jval.2020.10.004_bib9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1586\/14760584.7.6.753","article-title":"Cost-effectiveness of varicella vaccination programs: an update of the literature","volume":"7","author":"Rozenbaum","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.jval.2020.10.004_bib10","first-page":"133","article-title":"Economic evaluation of varicella vaccination programmes: a review of the literature","volume":"22","author":"Thiry","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"25","key":"10.1016\/j.jval.2020.10.004_bib11","first-page":"265","article-title":"Varicella and herpes zoster vaccines: WHO position paper, June 2014","volume":"89","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"year":"2015","series-title":"ECDC Guidance: Varicella Vaccination in the European Union","key":"10.1016\/j.jval.2020.10.004_bib12"},{"issue":"6","key":"10.1016\/j.jval.2020.10.004_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0066485","article-title":"Herpes Zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review","volume":"8","author":"Ogunjimi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2020.10.004_bib14","doi-asserted-by":"crossref","first-page":"e5012","DOI":"10.7717\/peerj.5012","article-title":"Evaluation of the effect of chickenpox vaccination on shingles epidemiology using agent-based modeling","volume":"6","author":"Rafferty","year":"2018","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.jval.2020.10.004_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.vaccine.2019.10.065","article-title":"Seeking the optimal schedule for chickenpox vaccination in Canada: using an agent-based model to explore the impact of dose timing, coverage and waning of immunity on disease outcomes","volume":"38","author":"Rafferty","year":"2020","journal-title":"Vaccine"},{"year":"2017","series-title":"Guidelines for the Economic Evaluation of Health Technologies","key":"10.1016\/j.jval.2020.10.004_bib16"},{"issue":"2","key":"10.1016\/j.jval.2020.10.004_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated health economic evaluation reporting standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"author":"McDonald","key":"10.1016\/j.jval.2020.10.004_bib18"},{"key":"10.1016\/j.jval.2020.10.004_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1471-2431-12-154","article-title":"Communicating with parents about vaccination: a framework for health professionals","volume":"12","author":"Leask","year":"2012","journal-title":"BMC Pediatr"},{"year":"2014","series-title":"Self-Reported Population Health: An International Perspective Based on EQ-5D","author":"Szende","key":"10.1016\/j.jval.2020.10.004_bib22"},{"issue":"11","key":"10.1016\/j.jval.2020.10.004_bib23","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1017\/S0950268811002640","article-title":"The health and economic burden of chickenpox and herpes zoster in Belgium","volume":"140","author":"Bilcke","year":"2012","journal-title":"Epidemiol Infect"},{"issue":"11","key":"10.1016\/j.jval.2020.10.004_bib24","first-page":"1211","article-title":"Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study","volume":"11","author":"Drolet","year":"2010","journal-title":"J\u00a0Pain"},{"issue":"6","key":"10.1016\/j.jval.2020.10.004_bib25","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.vaccine.2011.11.026","article-title":"The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom","volume":"30","author":"Van Hoek","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2020.10.004_bib26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1186\/s12879-016-1898-z","article-title":"Increasing incidence associated with herpes zoster infection in British Columbia, Canada","volume":"16","author":"Marra","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jval.2020.10.004_bib27","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1016\/j.vaccine.2013.09.018","article-title":"Shingles in Alberta: before\u00a0and after publicly funded varicella vaccination","volume":"32","author":"Russell","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2020.10.004_bib28","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/529043","article-title":"Primary vaccine failure after 1 dose of varicella vaccine in healthy children","volume":"197","author":"Michalik","year":"2008","journal-title":"J\u00a0Infect Dis"},{"issue":"2","key":"10.1016\/j.jval.2020.10.004_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","article-title":"Ten year follow-up of healthy children who received one or two injections of varicella vaccine","volume":"23","author":"Kuter","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"10.1016\/j.jval.2020.10.004_bib30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/01.inf.0000172902.25009.a1","article-title":"Evaluation of a quadrivalent measles, mumps, rubella, and varicella vaccine in healthy children","volume":"24","author":"Shinefield","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.jval.2020.10.004_bib31","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1097\/INF.0b013e31828b7def","article-title":"Primary versus secondary\u00a0failure\u00a0after varicella vaccination","volume":"32","author":"Bonanni","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.jval.2020.10.004_bib32","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1017\/S0950268800004714","article-title":"Modelling the impact of immunization on the epidemiology of varicella zoster virus","volume":"125","author":"Brisson","year":"2000","journal-title":"Epidemiol Infect"},{"issue":"13","key":"10.1016\/j.jval.2020.10.004_bib33","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.vaccine.2011.01.037","article-title":"Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England","volume":"29","author":"van Hoek","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jval.2020.10.004_bib34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/s12889-015-1861-8","article-title":"Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries","volume":"15","author":"Damm","year":"2015","journal-title":"BMC Public Health"},{"issue":"6","key":"10.1016\/j.jval.2020.10.004_bib35","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00006454-200206000-00012","article-title":"Instituting a routine varicella vaccination program in Canada: an economic evaluation","volume":"21","author":"Getsios","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"7-8","key":"10.1016\/j.jval.2020.10.004_bib36","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0264-410X(01)00437-6","article-title":"The cost-effectiveness of varicella vaccination in Canada","volume":"20","author":"Brisson","year":"2002","journal-title":"Vaccine"},{"issue":"1077","key":"10.1016\/j.jval.2020.10.004_bib37","first-page":"1","article-title":"Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox","volume":"7","author":"Ogunjimi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jval.2020.10.004_bib38","first-page":"9","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.jval.2020.10.004_bib39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1017\/S0950268800050019","article-title":"The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster","volume":"108","author":"Garnett","year":"1992","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jval.2020.10.004_bib40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/(SICI)1099-1654(199609)6:3<151::AID-RMV172>3.0.CO;2-V","article-title":"Predicting the effect of varicella vaccine on subsequent cases of zoster and varicella","volume":"6","author":"Garnett","year":"1996","journal-title":"Rev Med Virol"},{"issue":"47","key":"10.1016\/j.jval.2020.10.004_bib41","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1016\/j.vaccine.2011.09.024","article-title":"Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program","volume":"29","author":"Tanuseputro","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jval.2020.10.004_bib42","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/INF.0b013e3181acf84f","article-title":"Incidence of herpes zoster among children vaccinated with varicella vaccine in a prepaid health care plan in the United States, 2002-2008","volume":"28","author":"Tseng","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.jval.2020.10.004_bib43","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1097\/INF.0b013e3181a90b16","article-title":"The incidence and clinical characteristics\u00a0of herpes zoster among children and adolescents after implementation of varicella vaccination","volume":"28","author":"Civen","year":"2009","journal-title":"Pediatr Infect Dis J"},{"year":"2005","series-title":"Methods for Economic Evaluation of Health Care Programs","author":"Drummond","key":"10.1016\/j.jval.2020.10.004_bib44"},{"key":"10.1016\/j.jval.2020.10.004_bib45","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1016\/j.vaccine.2008.08.016","article-title":"Impact of varicella vaccination on health care outcomes in Ontario, Canada: effect of a publicly funded program?","volume":"26","author":"Kwong","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jval.2020.10.004_bib46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S0950268801005921","article-title":"Epidemiology of varicella zoster virus infection in Canada and the United Kingdom","volume":"127","author":"Brisson","year":"2001","journal-title":"Epidemiol Infect"},{"issue":"12","key":"10.1016\/j.jval.2020.10.004_bib47","first-page":"1","article-title":"The burden of varicella and zoster in British Columbia 1994-2003: baseline assessment prior to universal vaccination","volume":"33","author":"Edgar","year":"2007","journal-title":"Canada Commun Dis Rep"},{"issue":"1","key":"10.1016\/j.jval.2020.10.004_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12879-017-2185-3","article-title":"Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia","volume":"17","author":"Friesen","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.jval.2020.10.004_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.jval.2020.10.004_bib50","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1503\/cmaj.140078","article-title":"Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study","volume":"186","author":"MacDonald","year":"2014","journal-title":"CMAJ"},{"key":"10.1016\/j.jval.2020.10.004_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-018-5298-8","article-title":"Varicella in Poland: economic burden in children 1-12 years of age in Poland, 2010-2015","volume":"18","author":"Wysocki","year":"2018","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.jval.2020.10.004_bib53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12962-017-0066-7","article-title":"Costs and savings associated with a pharmacists prescribing for minor ailments program in Saskatchewan","volume":"15","author":"Rafferty","year":"2017","journal-title":"Cost Eff Resour Alloc"},{"issue":"6","key":"10.1016\/j.jval.2020.10.004_bib54","first-page":"356","article-title":"Pain, medication use, and\u00a0health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey","volume":"6","author":"Oster","year":"2005","journal-title":"J\u00a0Pain"},{"issue":"12","key":"10.1016\/j.jval.2020.10.004_bib55","doi-asserted-by":"crossref","first-page":"847","DOI":"10.4161\/hv.9898","article-title":"Economic evaluation of varicella vaccination in Swiss children and adolescents","volume":"5","author":"Banz","year":"2009","journal-title":"Hum Vaccin"},{"issue":"12","key":"10.1016\/j.jval.2020.10.004_bib58","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.vaccine.2012.01.045","article-title":"Employment related productivity\u00a0loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study","volume":"30","author":"Drolet","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jval.2020.10.004_bib59","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/BF03405265","article-title":"Cost analysis of public health influenza vaccine clinics in Ontario","volume":"100","author":"Mercer","year":"2009","journal-title":"Can J Public Heal"},{"issue":"1","key":"10.1016\/j.jval.2020.10.004_bib60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.12927\/hcq.2009.20411","article-title":"ED Spending in Canada: a focus on the cost of patients waiting for access to an in-patient bed in Ontario","volume":"12","author":"Dawson","year":"2009","journal-title":"Healthc Q"},{"key":"10.1016\/j.jval.2020.10.004_bib61","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1086\/512673","article-title":"Strategies to prevent varicella among newly arrived adult immigrants and refugees: a cost-effectiveness analysis","volume":"44","author":"Merrett","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2020.10.004_bib62","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.vaccine.2008.12.024","article-title":"Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales","volume":"27","author":"Hoek","year":"2009","journal-title":"Vaccine"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520344478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520344478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:22:29Z","timestamp":1761096149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520344478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1098301520344478"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.10.004","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}